Catalyst PharmaceuticalCPRX
Market Cap: $2.33B
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Employees: 167
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1% more funds holding
Funds holding: 265 [Q1] → 268 (+3) [Q2]
9% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 32
7% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 87
0.94% less ownership
Funds ownership: 83.07% [Q1] → 82.12% (-0.94%) [Q2]
4% less capital invested
Capital invested by funds: $1.56B [Q1] → $1.5B (-$57.3M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
34% less call options, than puts
Call options by funds: $522K | Put options by funds: $789K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Andrew Fein 47% 1-year accuracy 73 / 156 met price target | 53%upside $30 | Buy Maintained | 12 Aug 2024 |
Citigroup Samantha Semenkow 25% 1-year accuracy 4 / 16 met price target | 58%upside $31 | Buy Maintained | 9 Aug 2024 |
Truist Securities Joon Lee 60% 1-year accuracy 25 / 42 met price target | 53%upside $30 | Buy Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 5 articles about CPRX published over the past 30 days